These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17553741)

  • 1. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.
    Szalat A; Gershkovich P; Ben-Ari A; Shaish A; Liberman Y; Boutboul E; Gotkine M; Hoffman A; Harats D; Leitersdorf E; Meiner V
    Biochim Biophys Acta; 2007 Jul; 1771(7):839-44. PubMed ID: 17553741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
    Batta AK; Salen G; Tint GS
    Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
    Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
    Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
    Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
    Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27(-/-) mice and CTX.
    Honda A; Salen G; Matsuzaki Y; Batta AK; Xu G; Leitersdorf E; Tint GS; Erickson SK; Tanaka N; Shefer S
    J Lipid Res; 2001 Feb; 42(2):291-300. PubMed ID: 11181760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
    Keren Z; Falik-Zaccai TC
    Pediatr Endocrinol Rev; 2009 Sep; 7(1):6-11. PubMed ID: 19696711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
    Salen G; Steiner RD
    J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholestanol metabolism, molecular pathology, and nutritional implications.
    Seyama Y
    J Med Food; 2003; 6(3):217-24. PubMed ID: 14585188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could steroids mask the diagnosis of cerebrotendinous xanthomatosis?
    Siman-Tov T; Meiner V; Gadoth N
    J Neurol Sci; 2006 Apr; 243(1-2):83-6. PubMed ID: 16445943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.
    de Sain-van der Velden MG; Verrips A; Prinsen BH; de Barse M; Berger R; Visser G
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S387-93. PubMed ID: 18949577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
    Mignarri A; Magni A; Del Puppo M; Gallus GN; Björkhem I; Federico A; Dotti MT
    J Inherit Metab Dis; 2016 Jan; 39(1):75-83. PubMed ID: 26153518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.
    Fiorucci S; Distrutti E
    Handb Exp Pharmacol; 2019; 256():265-282. PubMed ID: 31267167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene.
    Rosen H; Reshef A; Maeda N; Lippoldt A; Shpizen S; Triger L; Eggertsen G; Björkhem I; Leitersdorf E
    J Biol Chem; 1998 Jun; 273(24):14805-12. PubMed ID: 9614081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
    Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
    Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
    Heller R; Grau AJ; Schäbitz WR; Schwaninger M
    Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene.
    Suh S; Kim HK; Park HD; Ki CS; Kim MY; Jin SM; Kim SW; Hur KY; Kim KW; Kim JH
    Eur J Med Genet; 2012 Jan; 55(1):71-4. PubMed ID: 21958693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.
    Salen G; Grundy SM
    J Clin Invest; 1973 Nov; 52(11):2822-35. PubMed ID: 4355999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis.
    van Heijst AF; Wevers RA; Tangerman A; Cruysberg JR; Renier WO; Tolboom JJ
    Acta Paediatr; 1996 Aug; 85(8):932-6. PubMed ID: 8863874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment.
    Martini G; Mignarri A; Ruvio M; Valenti R; Franci B; Del Puppo M; Federico A; Nuti R; Dotti MT
    Calcif Tissue Int; 2013 Mar; 92(3):282-6. PubMed ID: 23212544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
    Weissfeld T; Ratliff J
    J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.